Strait & Sound Wealth Management LLC Invests $1.92 Million in Amgen Inc. $AMGN

Strait & Sound Wealth Management LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,292 shares of the medical research company's stock, valued at approximately $1,916,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Adell Harriman & Carpenter Inc. grew its stake in shares of Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company's stock worth $7,204,000 after acquiring an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Amgen in the 4th quarter valued at approximately $22,441,000. Sigma Planning Corp boosted its stake in Amgen by 24.0% in the 4th quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company's stock worth $5,889,000 after purchasing an additional 3,488 shares in the last quarter. National Pension Service boosted its stake in Amgen by 4.7% in the 4th quarter. National Pension Service now owns 1,239,549 shares of the medical research company's stock worth $405,717,000 after purchasing an additional 55,489 shares in the last quarter. Finally, Integrated Advisors Network LLC grew its position in Amgen by 50.5% during the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock worth $6,664,000 after purchasing an additional 6,356 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Amgen Stock Down 1.0%

AMGN stock opened at $432.42 on Friday. The firm's fifty day simple moving average is $388.64 and its 200-day simple moving average is $364.71. The company has a market capitalization of $233.78 billion, a P/E ratio of 26.88, a price-to-earnings-growth ratio of 3.16 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the prior year, the business earned $6.02 earnings per share. The business's quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.92 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire expands its potential market. Amgen and AstraZeneca reported that Tezspire met both co-primary and all key secondary endpoints in the Phase 3 CROSSING study for eosinophilic esophagitis (EoE). Improvements in tissue inflammation and swallowing symptoms were statistically significant, clinically meaningful and sustained through 52 weeks. EoE could become Tezspire’s third approved indication, adding a potentially significant growth opportunity beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 EoE Results
• Positive Sentiment: Recent financial performance remains supportive. Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Strong results and full-year guidance have helped keep the stock near its 52-week high and provide a favorable backdrop for pipeline news. Amgen Earnings and Guidance
• Neutral Sentiment: Additional pipeline updates offer limited near-term valuation impact. Amgen provided updates on a pediatric psoriasis study involving apremilast and began a Phase 1 trial of AMG 691 aimed at markets in Asia. These programs may support long-term growth, but both remain too early to materially affect current earnings expectations. Amgen Pediatric Psoriasis Study
• Negative Sentiment: Amgen ended its Crohn’s disease research partnership with TScan Therapeutics. Terminating the collaboration removes an external source of potential inflammatory bowel disease assets and may raise questions about the company’s strategy in this research area. The impact is likely limited near term because the program was still focused on target discovery. Amgen Ends Crohn’s Research Partnership

Insider Activity

In other news, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company's stock.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. Erste Group Bank reissued a "hold" rating on shares of Amgen in a report on Tuesday, May 5th. Bank of America upped their target price on Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a research report on Wednesday, August 5th. Argus lifted their price target on Amgen from $375.00 to $460.00 and gave the stock a "buy" rating in a research report on Wednesday, August 19th. Finally, Piper Sandler boosted their price target on Amgen from $427.00 to $457.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Amgen presently has an average rating of "Hold" and a consensus target price of $380.43.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source